Exagen Inc.
A medical diagnostics company, Exagen makes blood tests that help rheumatologists tell apart autoimmune conditions like lupus and rheumatoid arthritis. Its flagship product, AVISE CTD, is processed in a single lab in Vista, California, with results typically ready in about five business days. Founded in 2002, the company grows its line of AVISE-branded tests, and the "CTD" in its flagship test's name stands for connective tissue disease—the family of illnesses it helps doctors sort out.
Sold 550.0K
Bought 167
Granted 818.3K · Bought 130.4K · Sold 92.7K
Granted 316.5K · Bought 22.3K · Sold 22.1K
Granted 238.5K · Sold 29.0K
Granted 163.5K · Sold 9.5K
Granted 75.0K
Granted 50.0K
Bought 1.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Sun Mountain Capital Partners LLC +1 co-filer10% owner · 2 transactions | -23.8% | 1.76Mas of Mar 2025 | — | — | 550.0K |
| Tullis James L L +1 co-filer10% owner · 1 transaction | — | 1.54Mas of Jun 2023 | — | 167 | — |
| Aballi JohnPresident and CEO, Director · 14 transactions | — | 880.2K | 818.3K | 130.4K | 92.7K |
| Black Jeffrey G.Chief Financial Officer · 7 transactions | — | 342.4K | 316.5K | 22.3K | 22.1K |
| Adawi KamalCFO and Corporate Secretary · 9 transactions | +559.3% | 247.2Kas of Mar 2024 | 238.5K | — | 29.0K |
| Hazeltine MarkChief Business Officer · 5 transactions | +382.3% | 190.2Kas of Mar 2023 | 163.5K | — | 9.5K |
| Rocca Fortunato R.President and CEO, Director · 2 transactions | +141.4% | 120.7Kas of Mar 2022 | 75.0K | — | — |
| Zack DebraChief Medical Officer · 2 transactions | +124.7% | 84.3Kas of Mar 2022 | 50.0K | — | — |
| Johnson Wendy S.Director · 1 transaction | — | 1.0Kas of Sep 2021 | — | 1.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -549.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.